Skip to main content
SpringerLink
Log in

Looking into the Future—Emerging Therapies Based on Pathogenesis

  • Chapter
  • First Online:
Sjögren’s Syndrome

  • 1496 Accesses

Abstract

Previously in this textbook, improvement in the knowledge on the pathogenesis of primary Sjögren’s syndrome (pSS) has already been emphasized as well as the absence of any specific drug for treatment of this disease. In this section, we will try to reconcile pathogenesis and treatment by focusing on the crucial pathogenic steps that could be targeted by emerging therapies. The main new insights into the pathogenesis of the disease are represented by the accumulating data on the involvement of type I interferon and the triggers of B-lymphocyte activation in pSS. First, we will summarize the pathogenic involvement of type I interferon (IFN) and B-cell-activating factor of the TNF family (BAFF) in B-cell activation. Interestingly, these recent genetic and pathogenic studies evidenced number of similarities between pSS and lupus, and pSS could be considered as a sort of lupus of mucosa. We will subsequently discuss the different therapeutics that could target such an IFN–BAFF–B-lymphocyte axis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos NM, Moutsopoulos HM. Foxp3+ T-regulatory cells in Sjogren’s syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors. Am J Pathol. 2008;173:1389–96.

    Article  PubMed  Google Scholar 

  2. Gottenberg JE, Lavie F, Abbed K, Gasnault J, Le Nevot E, Delfraissy JF, Taoufik Y, Mariette X. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjogren’s syndrome. J Autoimmun. 2005;24:235–42.

    Article  PubMed  CAS  Google Scholar 

  3. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren’s syndrome patients from healthy controls. Arthritis Rheum. 2005;52:1534–44.

    Article  PubMed  CAS  Google Scholar 

  4. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren’s syndrome. Proc Natl Acad Sci USA. 2006;103:2770–5.

    Article  PubMed  CAS  Google Scholar 

  5. Emamian ES, Leon JM, Lessard CJ, Grandits M, Baechler EC, Gaffney PM, Segal B, Rhodus NL, Moser KL. Peripheral blood gene expression profiling in Sjögren’s syndrome. Genes Immun. 2009;10:285–96. Epub 2009 Apr 30.

    Article  PubMed  CAS  Google Scholar 

  6. Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X. Association of an IRF5 gene functional polymorphism with Sjogren’s syndrome. Arthritis Rheum. 2007;56:3989–94.

    Article  PubMed  CAS  Google Scholar 

  7. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995–9.

    Article  PubMed  CAS  Google Scholar 

  8. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis. 2003;62:168–71.

    Article  PubMed  CAS  Google Scholar 

  9. Sellam J, Miceli-Richard C, Gottenberg JE, Ittah M, Lavie F, Lacabaratz C, Gestermann N, Proust A, Lambotte O, Mariette X. Decreased BAFF-R on peripheral lymphocytes associated with increased disease activity in primary Sjogren’s syndrome and systemic lupus erythematosus. Ann Rheum Dis. 2007 Jun;66:790–7.

    Article  PubMed  CAS  Google Scholar 

  10. Stein JV, López-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodríguez D, Gómez-Caro R, De Jong J, Martínez-A C, Medema JP, Hahne M. APRIL modulates B and T cell immunity. J Clin Invest. 2002;109:1587–98.

    PubMed  CAS  Google Scholar 

  11. Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37:829–34.

    Article  PubMed  CAS  Google Scholar 

  12. Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, Tumas D, Grewal IS, Dixit VM. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol. 2001;2:638–43.

    Article  PubMed  CAS  Google Scholar 

  13. Ittah M, Miceli-Richard C, Eric Gottenberg J, Lavie F, Lazure T, Ba N, Sellam J, Lepajolec C, Mariette X. B-cell activating factor of the TNF family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren’s syndrome. Arthritis Res Ther. 2006 8;R51

    Article  PubMed  Google Scholar 

  14. Kapsogeorgou E, Manoussakis MN, The central role of epithelial cells in Sjogren’s syndrome or autoimmune epithelitis. Autoimmun Rev. 2004;3(Suppl 1):S61–3.

    PubMed  Google Scholar 

  15. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Overexpression of BAFF in T cells infiltrating labial salivary glands from patients with Sjögren’s syndrome. J Pathol. 2004;202:496–502.

    Article  PubMed  CAS  Google Scholar 

  16. Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007;46:1083–6.

    Article  CAS  Google Scholar 

  17. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren’s syndrome. Scand J Immunol. 2008;67:185–92.

    Article  PubMed  CAS  Google Scholar 

  18. Daridon C, Devauchelle V, Hutin P, Le Berre R, Martins-Carvalho C, Bendaoud B, Dueymes M, Saraux A, Youinou P, Pers JO. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren’s syndrome. Arthritis Rheum. 2007 ;56:1134–44.

    Article  PubMed  CAS  Google Scholar 

  19. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, Cerutti A. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3:822–829.

    Article  PubMed  CAS  Google Scholar 

  20. Ittah M, Miceli-Richard C, Gottenberg JE, Sellam J, Eid P, Lebon P, Pallier C, Lepajolec C, Mariette X. Viruses induce high expression of B cell-activating factor by salivary gland epithelial cells through Toll-like receptor- and type-I interferon-dependent and -independent pathways. Eur J Immunol. 2008 Apr;38:1058–64.

    Article  PubMed  CAS  Google Scholar 

  21. Ittah M, Miceli-Richard C, Gottenberg JE, Sellam J, Lepajolec C, Mariette X. B-cell-activating factor expressions in salivary epithelial cells after dsRNA virus infection depends on RNA-activated protein kinase activation. Eur J Immunol. 2009;39:1271–9.

    Article  PubMed  CAS  Google Scholar 

  22. Gottenberg JE, Sellam J, Ittah M, Lavie F, Proust A, Zouali H, Sordet C, Sibilia J, Kimberly RP, Mariette X, Miceli-Richard C. No evidence for an association between the −871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren’s syndrome. Arthritis Res Ther. 2006;8:R30. Epub 2006 Jan 9. PubMed PMID: 16507129.

    Article  PubMed  Google Scholar 

  23. Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmström P, Wahren-Herlenius M, Jonsson R. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren’s syndrome. Arthritis Rheum. 2003;48:3187–3201.

    Article  PubMed  CAS  Google Scholar 

  24. Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren’s syndrome. A cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796–803.

    Article  PubMed  CAS  Google Scholar 

  25. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337–2344.

    Article  PubMed  Google Scholar 

  26. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104: 2247–53.

    Article  PubMed  CAS  Google Scholar 

  27. Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren’s syndrome. Arthritis Rheum. 2002;46:2730–41.

    Article  PubMed  CAS  Google Scholar 

  28. Barone F, Bombardieri M, Manzo A, Blades MC, Morgan PR, Challacombe SJ, Valesini G, Pitzalis C. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren’s syndrome. Arthritis Rheum. 2005;52:1773–84.

    Article  PubMed  CAS  Google Scholar 

  29. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren’s syndrome: findings in humans and mice. Arthritis Rheum. 2008;58:734–43.

    Article  PubMed  CAS  Google Scholar 

  30. Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, Sibilia J, Mariette X. In primary Sjogren’s syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003;48:2240–5.

    Article  PubMed  CAS  Google Scholar 

  31. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol. 2009 Jan 1;182:34–8.

    PubMed  CAS  Google Scholar 

  32. Dawson LJ, Fox PC, Smith PM. Sjogrens syndrome—the non-apoptotic model of glandular hypofunction. Rheumatology (Oxford) 2006;45:792–8.

    Article  CAS  Google Scholar 

  33. Ohlsson M, Skarstein K, Bolstad AI, Johannessen AC, Jonsson R. Fas-induced apoptosis is a rare event in Sjogren’s syndrome. Lab Invest. 2001;81:95–105.

    PubMed  CAS  Google Scholar 

  34. Zoukhri D, Kublin CL. Impaired neurotransmitter release from lacrimal and salivary gland nerves of a murine model of Sjogren’s syndrome. Invest Ophthalmol Vis Sci. 2001;42:925–32.

    PubMed  CAS  Google Scholar 

  35. Dawson LJ, Caulfield VL, Stanbury JB, Field AE, Christmas SE, Smith PM. Hydroxychloroquine therapy in patients with primary Sjogren’s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford) 2005;44:449–55.

    Article  CAS  Google Scholar 

  36. Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren’s syndrome. Arthritis Rheum. 2000;43:1647–54.

    Article  PubMed  CAS  Google Scholar 

  37. Beroukas D, Hiscock J, Jonsson R, Waterman SA, Gordon TP. Subcellular distribution of aquaporin 5 in salivary glands in primary Sjögren’s syndrome. Lancet 2001;358:1875–76.

    Article  PubMed  CAS  Google Scholar 

  38. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, Del Papa N, De Vita S, Epis O, Franceschini F, Gerli R, Govoni M, Bongi SM, Maglione W, Migliaresi S, Montecucco C, Orefice M, Priori R, Tavoni A, Valesini G. Sjögren’s syndrome disease damage index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56:2223–31.

    Article  PubMed  Google Scholar 

  39. Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E, Canavan A, Hamburger J, Richards A, Rauz S, Regan M, Gadsby K, Rigby S, Jones A, Mathew R, Mulherin D, Stevenson A, Nightingale P. Sjögren’s systemic clinical activity index (SCAI)—a systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome. Rheumatology (Oxford) 2007;46:1845–51.

    Article  CAS  Google Scholar 

  40. Seror R, Ravaud P, Bowman S, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C. EULAR Sjogren’s syndrome disease activity index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren’s syndrome. Ann Rheum Dis. 2009 Jun 28; Epub ahead of print.

    Google Scholar 

  41. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J. Inefficacy of infliximab in primary Sjögren’s syndrome. Results of the randomized controlled Trial of Remicade In Primary Sjögren’s Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.

    Article  PubMed  CAS  Google Scholar 

  42. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.

    Article  PubMed  CAS  Google Scholar 

  43. Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum. 2007;56:3995–4004.

    Article  PubMed  CAS  Google Scholar 

  44. Wallace DJ, Petri M, Olsen N, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56:S526.

    Google Scholar 

  45. Stohl W, Chatham W, Weisman M, et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum. 2005;52:S444

    Article  Google Scholar 

  46. Petri M, Furie R, Ginzler E, et al. Novel combined response endpoint and systemic lupus erythematosus (SLE) flare index (SFI) demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy. Arthritis Rheum. 2007;56:S527 (abstract 316).

    Google Scholar 

  47. Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818–20. Epub 2006 Dec 5.

    Article  PubMed  CAS  Google Scholar 

  48. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723–32.

    Article  PubMed  CAS  Google Scholar 

  49. Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 2007;56:1464–77.

    Article  PubMed  Google Scholar 

  50. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66:700–3.

    Article  PubMed  CAS  Google Scholar 

  51. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740–50.

    Article  PubMed  CAS  Google Scholar 

  52. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310–7.

    Article  PubMed  CAS  Google Scholar 

  53. Somer BG, Tsai DE, Downs L, et al. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum. 2003;49:394–8.

    Article  PubMed  Google Scholar 

  54. Voulgarelis M, Giannouli S, Tzioufas AG, et al. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033–7.

    Article  PubMed  CAS  Google Scholar 

  55. Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. Ann Rheum Dis. 2007;66:351–7.

    Article  PubMed  CAS  Google Scholar 

  56. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P. Reduction of fatigue in Sjogren’s syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis. 2008 Nov;67:1541–4.

    Article  PubMed  CAS  Google Scholar 

  57. Meijer J, Vissink A, Meiners PM, Spijkervet FKL, Kallenberg CGM, Bootsma H. Rituximab treatment in primary Sjögren’s syndrome: a double-blind placebo controlled trial. Arthritis Rheum. 2008;56:S430 (abstract 713).

    Google Scholar 

  58. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129.

    Article  PubMed  Google Scholar 

  59. Gatumu MK, Skarstein K, Papandile A, Browning JL, Fava RA, Bolstad AI. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren’s syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther. 2009;11:R24. Epub 2009 Feb 18.

    Article  PubMed  Google Scholar 

  60. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren’s syndrome. Hum Gene Ther. 2003;14:1605–18.

    Article  PubMed  CAS  Google Scholar 

  61. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, Baum BJ. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren’s syndrome. Ann Rheum Dis. 2006 Feb;65:195–200.

    Article  PubMed  CAS  Google Scholar 

  62. Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren’s syndrome. Rheumatology. 2004;43:1309–10.

    Article  PubMed  CAS  Google Scholar 

  63. Ramos-Casals M, López-Guillermo A, Brito-Zerón P, Cervera R, Font J, SS-HCV Study Group. Treatment of B-cell lymphoma with rituximab in two patients with Sjögren’s syndrome associated with hepatitis C virus infection. Lupus 2004;13:969–71.

    Article  PubMed  Google Scholar 

  64. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913–20.

    Article  PubMed  CAS  Google Scholar 

  65. Ahmadi-Simab K, Lamprecht P, Nölle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis. 2005;64:1087–8.

    Article  PubMed  CAS  Google Scholar 

  66. Ring T, Kallenbach M, Praetorius J, Nielsen S, Melgaard B. Successful treatment of a patient with primary Sjögren’s syndrome with rituximab. Clin Rheumatol. 2006 Nov;25(6):891–4. Epub 2005 Nov 8.

    Article  PubMed  Google Scholar 

  67. St. Clair E, Levesque MC, Luning Prak N, Vivino FB, Alappatt C, Wallace D, Wedgwood J, Cohen P. Rituximab therapy for primary Sjögren’s syndrome (pSS): an open-label trial. Arthritis Rheum. 2007;56:S449 (abstract 1102).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de Recherche Biomédical Strasbourgeois (CRBS), Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France

    Jacques-Eric Gottenberg

  2. Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Institut Pour la Santé et la Recherche Médicale (INSERM) U 1012, Université Paris-Sud 11, Le Kremlin Bicêtre, France

    Xavier Mariette

Authors
  1. Jacques-Eric Gottenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Mariette .

Editor information

Editors and Affiliations

  1. Research Foundation, Rheumatology Clinic, Scripps Memorial Hospital &, Caminito Sinnecock 6565, La Jolla, 92037, California, USA

    Robert I. Fox

  2. Research Foundation, Rheumatology Clinic, Scripps Memorial Hospital &, Caminito Sinnecock 6565, La Jolla, 92037, California, USA

    Carla M. Fox

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gottenberg, JE., Mariette, X. (2011). Looking into the Future—Emerging Therapies Based on Pathogenesis. In: Fox, R., Fox, C. (eds) Sjögren’s Syndrome. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-957-4_33

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-957-4_33

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-956-7

  • Online ISBN: 978-1-60327-957-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation